Keyphrases
Thyroid Cancer
100%
Sorafenib
100%
Differentiated Thyroid Cancer
66%
Fibrosarcoma
50%
Thyroid Patients
50%
Receptor Tyrosine Kinase
33%
FDA-approved Drugs
33%
Radioactive Iodine Refractory
33%
Clinical Application
16%
Mitogen-activated Protein Kinase
16%
Genetic Modification
16%
Clinical Development
16%
Dose Reduction
16%
Area Cover
16%
Poor Outcome
16%
Expert Opinion
16%
Progression-free Survival
16%
Risk-benefit
16%
Individual Risk
16%
Radioactive Iodine
16%
Discovery Strategy
16%
Side Effect Profile
16%
MAPK Cascade
16%
BRAF mutation
16%
Therapeutic Challenges
16%
Preclinical Development
16%
Overall Survival Benefit
16%
Advanced Differentiated Thyroid Cancer
16%
V600E-BRAF
16%
Radioiodine-refractory Differentiated Thyroid Cancer
16%
Metastatic Thyroid Cancer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Thyroid Cancer
100%
Sorafenib
100%
Differentiated Thyroid Cancer
100%
Radioactive Iodine
57%
Phosphotransferase
42%
Fibrosarcoma
42%
Protein Tyrosine Kinase
28%
Side Effect
14%
Recurrent Disease
14%
Progression Free Survival
14%
Overall Survival
14%